Novavax COVID-19 vaccine more than 90% effective in U.S trial according to Reuters. Despite positive news (which we do not trade), we will share with you our current view on Novavax.
a) The price is inside a descending Wedge, and due to positive news, we are observing a bullish GAP, and we may see the price outside the Wedge pattern
b) The general strategy...
Bullish news on cancer research and a looming patent publish date ETA June 1st. Earnings suck but they're shedding debt notes maybe for a buyout? Heads up on breakouts (short sellers wet dream). Cups within cups within cups. Dunno, DYOR and not investment advice.
-The company said that it has reached into a multi-program research collaboration and license agreement with Genentech, a member of the Roche Group, to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies that leverage Pieris’ proprietary Anticalin® technology.
-PIRS went on to explain that the collaboration will enable it...
#Ucugen breaking out of the ascending triangle.
- Trend continuation to 20.00 USD expected!
- Ocugen Inc. is a biopharmaceutical company focused on the development, development and commercialization therapies for eye diseases.
- Ocugen is developing a vaccine against COVID-19.
- Number of employees: 15 people.
After the disappointing Q1 results with sales of $12.1 billion while analysts were expecting sales of $12.6 billion and the company’s non-GAAP adjusted EPS that fell 7% Y/Y to $1.40 per share from the consensus estimates of $1.61 per share, i expect a retracement at the support level of $72/share for MRK.
The indicators remain bearish as well.
If you are...
This is an Elliot Wave projection suggesting we've just completed Wave 2 of a standard 5 Up formation.
Wave 2 is often a 0.5 or 0.618 pullback on Wave 1.
Wave 3 is often related to Wave 1 by 1:1, 1:1.618, or 1:2.618 (don't ask me why).
Wave 4 often pulls back to the .382 of Wave 3.
Wave 5 is least reliable and may replicate Wave 1 when Wave 3 extends, or...
This is not recent news, but the bear market in penny stocks made us forget about AVEO Oncology which announced that the National Comprehensive Cancer Network has updated its Clinical Practice Guidelines to include FOTIVDA® as a recommended regimen for subsequent therapy.
On March 10, 2021, the U.S. Food and Drug Administration approved FOTIVDA for the treatment...
Syndax Pharmaceuticals recently had POSITIVE interim data on their phase 2 study in SNDX-5613 for Leukemia. This data was positive as they saw a 48% overall response rate in patients with MLLr or NPM1c; 67% of responders achieved minimal residual disease-negative status. Out of 43 of patients evaluated, 31 were able to be used as for significant data. These two...
With a multi-year breakout and current pharma sector conditions, I believe it's going to outperform the sector.
Disclaimer: for education purposes only not recommended for trade.
can use both weekly and daily timeframe for getting the big picture.
Check the notes points for further clarity
First of all, I am not an expert when it comes to pharmaceutical companies!
Why did I pick Hepion Pharmaceuticals (@hepionpharma)?
1. From a business perspective, they are healthy (Quick Ration of Assets vs. Liabilities is 9 to 1)
2. They came from a super high share price and are currently on a super low level
3. They are working on a product CRV431 (recently...